Overview

Study of WST11 in Patients With Localized Prostate Cancer

Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
The aim of this clinical study is to determine the optimal treatment conditions to achieve prostate cancer tumor ablation and to assess the effects of WST11 mediated VTP treatment in patients with localized prostate cancer. The secondary objectives is to evaluate safety and quality of life ; to assess the pharmacokinetic parameters and to model the relationship between concentration and effects; and to assess the effects, the safety and quality of life of a second WST11 VTP treatment in patients with persistent or recurrent localized prostate cancer after a first VTP;
Phase:
Phase 2
Details
Lead Sponsor:
Steba Biotech S.A.